ISB 2001 — Investigational Agent
T-Cell Engager · Phase 1 · Ichnos Glenmark Innovation
Mechanism of Action
Trispecific antibody built on the BEAT platform that simultaneously binds BCMA and CD38 on malignant plasma cells and CD3 on T cells, driving avidity-enhanced T-cell redirected killing that may overcome low single-antigen density and antigen escape.
Investigational Indications
- Relapsed/refractory multiple myeloma